Natalizumab

CAS No. 189261-10-7

Natalizumab( —— )

Catalog No. M23864 CAS No. 189261-10-7

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 218 In Stock
5MG 392 In Stock
10MG 629 In Stock
25MG 938 In Stock
50MG 1237 In Stock
100MG 1665 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Natalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
  • Description
    Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    α4β1 integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    189261-10-7
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.
molnova catalog
related products
  • BMS-688521

    BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.

  • Lifitegrast sodium

    Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.

  • LLP2A

    LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM.